This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: guidelines

June 2024 Br J Cardiol 2024;31:65–8 doi:10.5837/bjc.2024.023

The 2023 ESC heart failure guideline update and its implications for clinical practice

Ameer Rashed, Mohammad Wasef, Paul R Kalra

Abstract

Introduction The European Society of Cardiology (ESC) heart failure guideline has undergone major updates every few years, with recent publications being in 2016 and 2021, respectively.1,2 Advances within heart failure care continue at pace, with presentation and publication of key randomised-controlled trials (RCTs) and meta-analyses being seen at the major cardiology scientific congresses. Given the likely impact of several trials on heart failure management and patient outcomes, the decision was made to publish a focused update in 2023 incorporating the most recent data.3 After robust review by the ESC guideline task force, only trials th

| Full text

July 2022 Br J Cardiol 2022;29(suppl 2):S2

What’s new in heart failure guidance – a user’s guide: Introduction

Paul Kalra

Abstract

This supplement provides a user’s guide to what’s new in the guidelines for the diagnosis and treatment of heart failure. This primarily relates to recommendations provided in the updated (2021) European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure. The articles summarise the contemporary guidance with respect to the diagnosis and investigation of patients presenting with heart failure; drug therapy (including the early implementation of the ‘four pillars’ of drug treatment for heart failure with reduced ejection fraction); and recommendations on lifestyle, rehabilitation,

| Full text

July 2022 Br J Cardiol 2022;29(suppl 2):S3–S6 doi:10.5837/bjc.2022.s06

New developments in the investigations and diagnosis of heart failure

Patricia Campbell

Abstract

Introduction The heart failure (HF) community has seen huge advances in the care of HF, and we see a turning point in the narrative of doom and gloom, which has traditionally been associated with HF – we see cause for optimism. We recognise the urgency of putting these advances to prompt use, as demonstrated by the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.1 The 2021 updated guidelines make it clear that we have the means to diagnose HF early, to classify it more accurately, the tools to change the HF trajectory, and the duty and ability to intervene – and to do so early. Diagnosis While the ESC diagnost

| Full text

January 2021 Br J Cardiol 2021;28:5–6 doi:10.5837/bjc.2021.004

ISCHEMIA trial: do the new stable chest pain guidelines need updating?

Khaled Alfakih, Saad Fyyaz, Andrew Wragg

Abstract

The recently published ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial is likely to change this practice.5 The ISCHEMIA trial compared medical therapy with invasive management in patients with proven ischaemia, after excluding patients with left main stem (LMS) stenosis with CTCA, and found no difference in outcome. We suggest that the ISCHEMIA trial results are likely to shift clinical practice towards CTCA as the primary diagnostic test for new chest pain. Current guidelines The updated ESC guidelines1 on new stable chest pain, published in 2019, recommended investigation based o

| Full text
The PIONEER AF-PCI study: its implications for everyday practice in the UK

August 2018 Br J Cardiol 2018;25(suppl 1):S12–S15 doi:10.5837/bjc.2018.s03

The PIONEER AF-PCI study: its implications for everyday practice in the UK

Jason Glover

Abstract

Introduction We are in a challenging era of increasing use of coronary stenting for coronary artery disease (CAD) in the UK,1 in conjunction with a growing population of patients with atrial fibrillation (AF) predominantly driven by age, hypertension, obesity and diabetes.2 Inevitably, these two common diseases, with similar risk factors, occur simultaneously in a significant proportion (5 to 8%) of patients undergoing revascularisation.3-5 This equates to an estimated 4,500 to 7,200 patients in the UK population, based upon British Cardiovascular Intervention Society (BCIS) data in 2014.1 Atrial phase thrombus has a stasis and fibrin drive,

| Full text
Acute heart failure – a call to action

March 2013 Br J Cardiol 2013;20(suppl 2):S1–S11 doi:10.5837/bjc.2013.s02

Acute heart failure – a call to action

Professor Martin Cowie, Professor Derek Bell, Mrs Jane Butler, Professor Henry Dargie, Professor Alasdair Gray, Professor Theresa McDonagh, Dr Hugh McIntyre, Professor Iain Squire, Dr Jacqueline Taylor, Ms Helen Williams

Abstract

(more…)

| Full text
Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice

March 2013 Br J Cardiol 2013;20(suppl 1): S1–S16 doi:10.5837/bjc.2013.s01

Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice

Dr Terry McCormack, Dr Chris Arden, Dr Alan Begg, Professor Mark Caulfield, Dr Kathryn Griffith, Ms Helen Williams

Abstract

(more…)

| Full text
Feasibility of using CTCA in patients with acute low-to-intermediate likelihood chest pain in a DGH

February 2013 Br J Cardiol 2013;20:39 doi:10.5837/bjc.2013.002 Online First

Feasibility of using CTCA in patients with acute low-to-intermediate likelihood chest pain in a DGH

Michael Michail, Shubra Sinha, Mohamed Albarjas, Kate Gramsma, Toby Rogers, Jonathan Hill, Khaled Alfakih

Abstract

Introduction Multi-detector computed tomography coronary angiography (CTCA) is becoming increasingly available in UK Hospitals. The National Institute for Health and Clinical Excellence (NICE) clinical guideline 95, released in 2010, recommended the use of calcium score ± CTCA in patients with low likelihood chest pain of recent onset.1 American College of Cardiology (ACC)/American Heart Association (AHA) appropriateness criteria for CTCA recommend its use in patients with low or intermediate likelihood chest pain.2 The rationale for the recommendations of CTCA is its excellent negative-predictive value.3 A further important point is that fu

| Full text

August 2012 Br J Cardiol 2012;19:107–10

New ESC Guidelines on heart failure and CVD prevention

News from the world of cardiology

Abstract

Heart failure The recommendations on devices, drugs and diagnosis in heart failure were developed by the ESC in collaboration with a heart failure association of the ESC. There have been several major updates since the previous guidance published in 2008.  The new updates include: In devices, left ventricular assist devices (LVADs) have been hailed as a step change in the management of heart failure. LVADs are more reliable and lead to fewer complications than in 2008. Until now, LVADs have been used as a temporary measure in patients awaiting a heart transplant. Professor John McMurray (Glasgow, UK), chairperson of the ESC Clinical Practice

| Full text
In brief

August 2012 Br J Cardiol 2012;19:112–3

In brief

BJCardio Staff

Abstract

EVINCI study completed The prevalence of “significant” coronary artery disease in patients with chest pain symptoms is lower than expected in Europe, according to preliminary findings from the The EValuation of INtegrated Cardiac Imaging (EVINCI) study. Once the final analysis is completed, the EVINCI study is expected to demonstrate that performing adequate non-invasive imaging screening of patients with suspected coronary artery disease could safely avoid invasive procedures in 75 out of 100 patients.  The study will have sufficient power to answer the question of which is the most cost-effective non-invasive imaging strategy for the j

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now